Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins – thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients worldwide. And as the world population ages, Alzheimer’s is quickly becoming a major global health concern. While there’s still a lot of research going on to understand exactly the root causes of Alzheimer’s, defective Tau proteins seem to be a definite hallmark of this and other neurodegenerative diseases (tauopathies). Fig. 1: Comparison of Tau protein’s normal function in the neuron with its pathological form. One of the Biotechs targeting Tau proteins is Axon Neuroscience (Slovakia),…


Link to Full Article: Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial